View Item 

Show simple item record

Overcoming Cancer Multidrug Resistance by Codelivery of Doxorubicin and Verapamil with Hydrogel Nanoparticles

dc.contributor.authorQin, Mingen_US
dc.contributor.authorLee, Yong‐eun Kooen_US
dc.contributor.authorRay, Aniruddhaen_US
dc.contributor.authorKopelman, Raoulen_US
dc.date.accessioned2014-09-03T16:51:32Z
dc.date.availableWITHHELD_12_MONTHSen_US
dc.date.available2014-09-03T16:51:32Z
dc.date.issued2014-08en_US
dc.identifier.citationQin, Ming; Lee, Yong‐eun Koo ; Ray, Aniruddha; Kopelman, Raoul (2014). "Overcoming Cancer Multidrug Resistance by Codelivery of Doxorubicin and Verapamil with Hydrogel Nanoparticles." Macromolecular Bioscience 14(8): 1106-1115.en_US
dc.identifier.issn1616-5187en_US
dc.identifier.issn1616-5195en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/108282
dc.description.abstractThe efficacy of chemotherapy is often inhibited by multidrug resistance (MDR). A highly engineerable hydrogel nanoparticle (NP) serves as a carrier for the optimal codelivery to tumor cells of the chemodrug, doxorubicin (Dox) and the chemosensitizer, verapamil (Vera), aiming at alleviating tumor MDR. The hydrogel NPs are prepared via the copolymerization of acrylamide and 2‐carboxyethyl acrylate. Dox and Vera are post‐loaded into the respective NPs, with drug loading around 7.7 wt% and 8.0 wt%, respectively. The codelivery of Dox‐NPs and Vera‐NPs increases the intracellular accumulation of Dox, and significantly enhances the cell killing ability of Dox with respect to NCI/ADR‐RES cells in vitro. These findings suggest that such codelivery nanoplatforms provide a promising route for overcoming tumor MDR. A new kind of hydrogel nanoparticles is developed as a delivery vehicle for codelivery of doxorubicin, an anti‐cancer drug (affects DNA), and verapamil, a chemosensitizer (blocks efflux pump), to tumor cells, aiming at overcoming multidrug resistance.en_US
dc.publisherHumana Pressen_US
dc.publisherWiley Periodicals, Inc.en_US
dc.subject.otherVerapamilen_US
dc.subject.otherMultidrug Resistanceen_US
dc.subject.otherHydrogel Nanoparticlesen_US
dc.subject.otherDoxorubicinen_US
dc.subject.otherCancer Therapyen_US
dc.titleOvercoming Cancer Multidrug Resistance by Codelivery of Doxorubicin and Verapamil with Hydrogel Nanoparticlesen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelMaterials Science and Engineeringen_US
dc.subject.hlbsecondlevelBiological Chemistryen_US
dc.subject.hlbsecondlevelChemical Engineeringen_US
dc.subject.hlbsecondlevelChemistryen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.subject.hlbtoplevelScienceen_US
dc.subject.hlbtoplevelEngineeringen_US
dc.description.peerreviewedPeer Revieweden_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/108282/1/mabi201400035.pdf
dc.identifier.doi10.1002/mabi.201400035en_US
dc.identifier.sourceMacromolecular Bioscienceen_US
dc.identifier.citedreferenceR. Kopelman, Y. E. L. Koo, M. Philbert, B. A. Moffat, G. R. Reddy, P. McConville, D. E. Hall, T. L. Chenevert, M. S. Bhojani, S. M. Buck, A. Rehemtulla, B. D. Ross, J. Magn. Magn. Mater. 2005, 293, 404.en_US
dc.identifier.citedreferenceL. J. Yu, J. Matias, D. A. Scudiero, K. M. Hite, A. Monks, E. A. Sausville, D. J. Waxman, Drug Metab. Dispos. 2001, 29, 304.en_US
dc.identifier.citedreferenceC. Pauli‐Magnus, O. von Richter, O. Burk, A. Ziegler, T. Mettang, M. Eichelbaum, M. F. Fromm, J. Pharmacol. Exp. Therap. 2000, 293, 376.en_US
dc.identifier.citedreferenceR. Sadasivan, R. Morgan, C. Fabian, R. Stephens, Cancer Lett. 1991, 57, 165.en_US
dc.identifier.citedreferenceL. S. Jabr‐Milane, L. E. van Vlerken, S. Yadav, M. M. Amiji, Cancer Treatment Rev. 2008, 34, 592.en_US
dc.identifier.citedreferenceL. Wu, A. M. Smythe, S. F. Stinson, L. A. Mullendore, A. Monks, D. A. Scudiero, K. D. Paull, A. D. Koutsoukos, L. V. Rubinstein, M. R. Boyd, R. H. Shoemaker, Cancer Res. 1992, 52, 3029.en_US
dc.identifier.citedreferenceF. Shen, S. Chu, A. K. Bence, B. Bailey, X. Xue, P. A. Erickson, M. H. Montrose, W. T. Beck, L. C. Erickson, J. Pharmacol. Exp. Therap. 2008, 324, 95.en_US
dc.identifier.citedreferenceJ. H. Beijnen, O. A. G. J. van der Houwen, W. J. M. Underberg, Int. J. Pharm. 1986, 32, 123.en_US
dc.identifier.citedreferenceD. Missirlis, R. Kawamura, N. Tirelli, J. A. Hubbell, Eur. J. Pharmaceut. Sci. 2006, 29, 120.en_US
dc.identifier.citedreferenceM. Dadsetan, Z. Liu, M. Pumberger, C. V. Giraldo, T. Ruesink, L. Lu, M. J. Yaszemski, Biomaterials 2010, 31, 8051.en_US
dc.identifier.citedreferenceM. J. H. Janssen, D. J. A. Crommelin, G. Storm, A. Hulshoff, Int. J. Pharm. 1985, 23, 1.en_US
dc.identifier.citedreferenceG. Nie, H. J. Hah, G. Kim, Y.‐E. K. Lee, M. Qin, T. S. Ratani, P. Fotiadis, A. Miller, A. Kochi, D. Gao, T. Chen, D. A. Orringer, O. Sagher, M. A. Philbert, R. Kopelman, Small 2012, 8, 884.en_US
dc.identifier.citedreferenceY.‐E. K. Lee, R. Kopelman, “ Targeted, Multifunctional Hydrogel Nanoparticles for Imaging and Treatment of Cancer: Multifunctional Nanoparticles for Drug Delivery Applications ”, S. Svenson, R. K. Prud'homme, Eds., Springer, Berlin/New York 2012, p. 225.en_US
dc.identifier.citedreferenceB. Ross, A. Rehemtulla, Y. E. L. Ko, R. Reddy, G. Kim, C. Behrend, S. Buck, R. J. Schneider, M. A. Philbert, R. Weissleder, R. Kopelman, Proc. SPIE 2004, 5331, 76.en_US
dc.identifier.citedreferenceN. Pallua, T. P. Wolter, Plast. Reconstruct. Surg. 2010, 125, 1797.en_US
dc.identifier.citedreferenceG. R. Reddy, M. S. Bhojani, P. McConville, J. Moody, B. A. Moffat, D. E. Hall, G. Kim, Y. E. L. Koo, M. J. Woolliscroft, J. V. Sugai, T. D. Johnson, M. A. Philbert, R. Kopelman, A. Rehemtulla, B. D. Ross, Clin. Cancer Res. 2006, 12, 6677.en_US
dc.identifier.citedreferenceH. Xu, S. M. Buck, R. Kopelman, M. A. Philbert, M. Brasuel, B. D. Ross, A. Rehemtulla, Isr. J. Chem. 2004, 44, 317.en_US
dc.identifier.citedreferenceJ. A. Harrel, R. Kopelman, Biophotonics Int. 2000, 7, 22.en_US
dc.identifier.citedreferenceS. Wang, G. Kim, Y.‐E. K. Lee, H. J. Hah, M. Ethirajan, R. K. Pandey, R. Kopelman, ACS Nano 2012, 6, 6843.en_US
dc.identifier.citedreferenceM. A. M. Capella, L. S. Capella, J. Biomed. Sci. 2003, 10, 361.en_US
dc.identifier.citedreferenceG. Szakacs, J. K. Paterson, J. A. Ludwig, C. Booth‐Genthe, M. M. Gottesman, Nat. Rev. Drug Discovery 2006, 5, 219.en_US
dc.identifier.citedreferenceE. Crowley, C. McDevitt, R. Callaghan, “ Generating Inhibitors of P‐Glycoprotein: Where to, Now? ”, in Multi‐Drug Resistance in Cancer, J. Zhou, Ed., Humana Press, Totowa, NJ 2010, p. 405.en_US
dc.identifier.citedreferenceA. Palmeira, E. Sousa, M. H. Vasconcelos, M. M. Pinto, Curr. Med. Chem. 2012, 19, 1946.en_US
dc.identifier.citedreferenceR. F. Ozols, R. E. Cunnion, R. W. Klecker, T. C. Hamilton, Y. Ostchega, J. E. Parrillo, R. C. Young, J. Clin. Oncol. 1987, 5, 641.en_US
dc.identifier.citedreferenceC.‐M. J. Hu, S. Aryal, L. Zhang, Therap. Delivery 2010, 1, 323.en_US
dc.identifier.citedreferenceY. E. L. Koo, G. R. Reddy, M. Bhojani, R. Schneider, M. A. Philbert, A. Rehemtulla, B. D. Ross, R. Kopelman, Adv. Drug Delivery Rev. 2006, 58, 1556.en_US
dc.identifier.citedreferenceM. E. Davis, Z. Chen, D. M. Shin, Nat. Rev. Drug Discovery 2008, 7, 771.en_US
dc.identifier.citedreferenceM. Susa, A. K. Iyer, K. Ryu, F. J. Hornicek, H. Mankin, M. M. Amiji, Z. F. Duan, BMC Cancer 2009, 9, 399.en_US
dc.identifier.citedreferenceI. Winer, S. Wang, Y.‐E. K. Lee, W. Fan, Y. Gong, D. Burgos‐Ojeda, G. Spahlinger, R. Kopelman, R. J. Buckanovich, Cancer Res. 2010, 70, 8674.en_US
dc.identifier.citedreferenceH. Meng, M. Liong, T. Xia, Z. Li, Z. Ji, J. I. Zink, A. E. Nel, ACS Nano 2010, 4, 4539.en_US
dc.identifier.citedreferenceA. Khdair, H. Handa, G. Z. Mao, J. Panyam, Eur. J. Pharm. Biopharm. 2009, 71, 214.en_US
dc.identifier.citedreferenceM. Gaumet, A. Vargas, R. Gurny, F. Delie, Eur. J. Pharm. Biopharm. 2008, 69, 1.en_US
dc.identifier.citedreferenceJ. Wang, B. Goh, W. Lu, Q. Zhang, A. Chang, X. Y. Liu, T. M. C. Tan, H. Lee, Biol. Pharm. Bull. 2005, 28, 822.en_US
dc.identifier.citedreferenceJ. Wu, Y. Lu, A. Lee, X. Pan, X. Yang, X. Zhao, R. J. Lee, J. Pharm. Pharmaceut. Sci. 2007, 10, 8.en_US
dc.identifier.citedreferenceT. A. Theodossiou, M. C. Galanou, C. M. Paleos, J. Med. Chem. 2008, 51, 6067.en_US
dc.identifier.citedreferenceH. L. Wong, R. Bendayan, A. M. Rauth, X. Y. Wu, J. Controlled Release 2006, 116, 275.en_US
dc.identifier.citedreferenceL. Fan, F. Li, H. Zhang, Y. Wang, C. Cheng, X. Li, C‐h. Gu, Q. Yang, H. Wu, S. Zhang, Biomaterials 2010, 31, 5634.en_US
dc.identifier.citedreferenceP.‐Y. Li, P.‐S. Lai, W.‐C. Hung, W.‐J. Syu, Biomacromolecules 2010, 11, 2576.en_US
dc.identifier.citedreferenceM.‐J. Shieh, C.‐Y. Hsu, L.‐Y. Huang, H.‐Y. Chen, F.‐H. Huang, P.‐S. Lai, J. Controlled Release 2011, 152, 418.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
mabi201400035.pdf
Size:
1.021MB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.